drugset / Trial / NCT01928576
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
Phase 2
Completed
143 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bristol-Myers Squibb · collabCelgene Corporation · collabRhone-Poulenc Rorer · collabRising Tide Foundation · collabStand Up To Cancer · collabSyndax Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Response Rate
Timeline
- Start
- 2013-11-06
- Primary completion
- 2023-04-04
- Completion
- 2023-04-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 40 mg/m2 | Subcutaneous |
| Subject | Azacitidine | Other / unclassified | 300 mg | Oral |
| Subject | Entinostat | Small molecule | 5 mg | Oral |
| Subject | Entinostat | Small molecule | 7 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | — |